Literature DB >> 24060874

Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

George Michail1, Maria Labrou, Vassiliki Pitiriga, Styliani Manousaka, Nikolaos Sakellaridis, Athanasios Tsakris, Spyros Pournaras.   

Abstract

Limited antimicrobials remain active for treating severe infections due to KPC-producing pathogens, and optimal regimens have not been established. In murine thigh infections caused by nine KPC-producing clinical strains of Enterobacteriaceae (meropenem MICs, 1 to 4 μg/ml), we evaluated the activities of tigecycline, colistin, meropenem, rifampin, and gentamicin in single and combination regimens lasting for 24 h and 48 h. Rifampin, tigecycline, and gentamicin were the most effective monotherapies, reducing significantly the CFU counts yielded from thighs infected by 88.9 to 100%, 77.8 to 88.9%, and 66.7 to 88.9% of strains, respectively; meropenem and colistin alone exhibited considerably lower performance (significant CFU reduction in 33.3% and 22.2 to 33.3% of the strains, respectively). The addition of rifampin or gentamicin to tigecycline produced synergistic effect in most strains, while antagonism was observed in 33.3 to 44.4% of the strains when colistin was added to tigecycline and in 44.4 to 55.5% of the strains for meropenem combination with tigecycline. Tigecycline combinations with gentamicin or with rifampin caused higher CFU reductions than did tigecycline plus colistin or plus meropenem with almost all strains. Furthermore, tigecycline plus gentamicin was significantly more effective than tigecycline plus colistin or tigecycline plus meropenem in 33.3 to 44.4% and 55.5 to 66.7% of the strains, respectively, while tigecycline plus rifampin significantly outperformed tigecycline plus colistin and tigecycline plus meropenem in 33.3% and 66.7 to 77.8% of the strains, respectively. Overall, our in vivo study showed that tigecycline plus rifampin or plus gentamicin is a robust regimen against soft tissue infections caused by KPC-producing strains. The combinations of tigecycline with colistin or meropenem should be considered with caution in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24060874      PMCID: PMC3837854          DOI: 10.1128/AAC.00891-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.

Authors:  Kenneth N Agwuh; Alasdair MacGowan
Journal:  J Antimicrob Chemother       Date:  2006-07-01       Impact factor: 5.790

2.  In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.

Authors:  Peter J Petersen; Ponpen Labthavikul; C Hal Jones; Patricia A Bradford
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

3.  In vivo pharmacodynamics of a new oxazolidinone (linezolid).

Authors:  D Andes; M L van Ogtrop; J Peng; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

5.  Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.

Authors:  Javier Cobo; María-Isabel Morosini; Vicente Pintado; Marta Tato; Noemí Samaranch; Fernando Baquero; Rafael Cantón
Journal:  Diagn Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 2.803

6.  Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.

Authors:  Sharath S Hegde; Noe Reyes; Robert Skinner; Stacey Difuntorum
Journal:  J Antimicrob Chemother       Date:  2007-11-09       Impact factor: 5.790

7.  In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus.

Authors:  Alexandros Ikonomidis; George Michail; Afroditi Vasdeki; Maria Labrou; Vasilis Karavasilis; Constantinos Stathopoulos; Antonios N Maniatis; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

8.  Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.

Authors:  Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  Endogenous IL-10 leads to impaired bacterial clearance and reduced survival in a murine model of chronic peritonitis.

Authors:  Andreas M Lenz; Glen A Franklin; Mark Fairweather; Michael L McClintock; Venkatakrishna R Jala; James C Peyton; Sarah A Gardner; William G Cheadle
Journal:  Cytokine       Date:  2007-11-28       Impact factor: 3.861

Review 10.  Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.

Authors:  Grace C Lee; David S Burgess
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-12-13       Impact factor: 3.944

View more
  20 in total

1.  In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.

Authors:  Jonathan W Betts; Lynette M Phee; Michael Hornsey; Neil Woodford; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Authors:  Zackery P Bulman; Michael J Satlin; Liang Chen; Barry N Kreiswirth; Beom Soo Shin; Thomas J Walsh; Patricia N Holden; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.

Authors:  Sheng Bi; Xin Yao; Cheng Huang; Xia Zheng; Tianming Xuan; Jifang Sheng; Kaijin Xu; Beiwen Zheng; Qing Yang
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

4.  In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates.

Authors:  Yongbo Zhang; Peizhen Li; Yuhan Yin; Fuqiang Li; Qinghua Zhang
Journal:  J Antibiot (Tokyo)       Date:  2016-07-27       Impact factor: 2.649

5.  Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.

Authors:  Paula Virginia Michelon Toledo; Ayrton Alves Aranha Junior; Lavinia Nery Arend; Vanessa Ribeiro; Alexandre Prehn Zavascki; Felipe Francisco Tuon
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

8.  Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.

Authors:  Isabel Machuca; Belén Gutiérrez-Gutiérrez; Irene Gracia-Ahufinger; Francisco Rivera Espinar; Ángela Cano; Julia Guzmán-Puche; Elena Pérez-Nadales; Clara Natera; Marina Rodríguez; Rafael León; Juan J Castón; Fernando Rodríguez-López; Jesús Rodríguez-Baño; Julián Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 9.  Synergistic combinations of polymyxins.

Authors:  Justin R Lenhard; Roger L Nation; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-10-24       Impact factor: 5.283

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.